Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC

This study is testing personalised treatment strategies for people with locally advanced esophageal squamous cell carcinoma (a type of throat/food-pipe cancer) before surgery, using biomarkers — including a protein called PD-L1 — to guide which combination of chemotherapy and immunotherapy to use. **You may be eligible if...** - You have been confirmed by biopsy to have esophageal squamous cell carcinoma - Your cancer is locally advanced (Stage II or III) and can potentially be removed by surgery - You are between 18 and 75 years old - Your overall health is good (ECOG performance status 0 or 1) - Your PD-L1 expression level has been tested - A thoracic surgeon has confirmed you are eligible for surgical resection - Your blood counts, liver, and kidney function are within acceptable ranges **You may NOT be eligible if...** - Your cancer has spread to distant organs - You have had another cancer in the past 5 years (with some exceptions) - You have active autoimmune disease requiring systemic treatment in the past 2 years - You have an active infection requiring treatment - You have other serious uncontrolled medical conditions Talk to your doctor to see if this trial is right for you.